|
1
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inoue A, Kobayashi K, Usui K, et al:
First-line gefitinib for patients with advanced non-small-cell lung
cancer harboring epidermal growth factor receptor mutations without
indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maemondo M, Minegishi Y, Inoue A, et al:
First-line gefitinib in patients aged 75 or older with advanced
non-small cell lung cancer harboring epidermal growth factor
receptor mutations: NEJ 003 study. J Thorac Oncol. 7:1417–1422.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hotta K, Ueoka H, Kiura K, et al: Safety
and efficacy of gefitinib treatment in elderly patients with
non-small-cell lung cancer: Okayama Lung Cancer Study Group
experience. Acta Oncol. 44:717–722. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bunn PA Jr and Lilenbaum R: Chemotherapy
for elderly patients with advanced non-small-cell lung cancer. J
Natl Cancer Inst. 95:341–343. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Owonikoko TK, Ragin CC, Belani CP, et al:
Lung cancer in elderly patients: an analysis of the surveillance,
epidemiology, and end results database. J Clin Oncol. 25:5570–5577.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi M, Matsui K, Katakami N, et al
West Japan Oncology Group: Phase II study of gefitinib as a
first-line therapy in elderly patients with pulmonary
adenocarcinoma: West Japan thoracic oncology group study 0402. Jpn
J Clin Oncol. 41:948–952. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uruga H, Kishi K, Fujii T, et al: Efficacy
of gefitinib for elderly patients with advanced non-small cell lung
cancer harboring epidermal growth factor receptor gene mutations: a
retrospective analysis. Intern Med. 49:103–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Asami K, Koizumi T, Hirai K, et al:
Gefitinib as first-line treatment in elderly epidermal growth
factor receptor-mutated patients with advanced lung adenocarcinoma:
results of a Nagano Lung Cancer Research Group study. Clin Lung
Cancer. 12:387–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rossi D, Dennetta D, Ugolini M, et al:
Activity and safety of erlotinib as second- and third-line
treatment in elderly patients with advanced non-small cell lung
cancer: a phase II trial. Target Oncol. 5:231–235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jackman DM, Yeap BY, Lindeman NI, et al:
Phase II clinical trial of chemotherapy-naive patients > or = 70
years of age treated with erlotinib for advanced non-small-cell
lung cancer. J Clin Oncol. 25:760–766. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Togashi Y, Masago K, Fujita S, et al:
Differences in adverse events between 250 mg daily gefitinib and
150 mg daily erlotinib in Japanese patients with non-small cell
lung cancer. Lung Cancer. 74:98–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida K, Yatabe Y, Park JY, et al:
Prospective validation for prediction of gefitinib sensitivity by
epidermal growth factor receptor gene mutation in patients with
non-small cell lung cancer. J Thorac Oncol. 2:22–28. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goldstraw P, Crowley J, Chansky K, et al
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions: The
IASLC Lung Cancer Staging Project: proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA1, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ebi N, Semba H, Tokunaga SJ, et al: A
phase II trial of gefitinib monotherapy in chemotherapy-naive
patients of 75 years or older with advanced non-small cell lung
cancer. J Thorac Oncol. 3:1166–1171. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tateishi K, Ichiyama T, Hirai K, et al:
Clinical outcomes in elderly patients administered gefitinib as
first-line treatment in epidermal growth factor receptor-mutated
non-small-cell lung cancer: retrospective analysis in a Nagano Lung
Cancer Research Group study. Med Oncol. 30:4502013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chrischilles EA, Pendergast JF, Kahn KL,
et al: Adverse events among the elderly receiving chemotherapy for
advanced non-small-cell lung cancer. J Clin Oncol. 28:620–627.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wheatley-Price P, Ding K, Seymour L, Clark
GM and Shepherd FA: Erlotinib for advanced non-small-cell lung
cancer in the elderly: an analysis of the National Cancer Institute
of Canada Clinical Trials Group study BR.21. J Clin Oncol.
26:2350–2357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kudoh S, Kato H, Nishiwaki Y, et al:
Interstitial lung disease in Japanese patients with lung cancer: a
cohort and nested case-control study. Am J Respir Crit Care Med.
177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Satoh H, Inoue A, Kobayashi K, et al:
Low-dose gefitinib treatment for patients with advanced non-small
cell lung cancer harboring sensitive epidermal growth factor
receptor mutations. J Thorac Oncol. 6:1413–1417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goto K, Nishio M, Yamamoto N, et al: A
prospective, phase II, open-label study (JO22903) of first-line
erlotinib in Japanese patients with epidermal growth factor
receptor (EGFR) mutation-positive advanced non-small-cell lung
cancer (NSCLC). Lung Cancer. 82:109–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
